Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17

Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17

297215

Oral Aubagio Approved in EU for Children With RRMS, Ages 10-17

The European Commission (EC) has approved Aubagio (teriflunomide) for the treatment of children and adolescents, ages 10 to 17, with relapsing-remitting multiple sclerosis (RRMS). Aubagio, approved for adults with RRMS since 2013, is now the first oral therapy available as a first-line treatment for pediatric patients in the European Union (EU). The expansion also provides an additional year of marketing protection in the EU, according to Aubagio’s developer, Sanofi. “The European approval of Aubagio in pediatrics means young…

You must be logged in to read/download the full post.